[{"id":"abcecb4f-2b74-48fe-9f6e-6aafd6ad4311","acronym":"","url":"https://clinicaltrials.gov/study/NCT04906473","created_at":"2021-05-28T13:52:37.952Z","updated_at":"2024-07-02T16:36:29.699Z","phase":"Phase 1","brief_title":"Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04906473","lead_sponsor":"Kunming Pharmaceuticals, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KY100001"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 07/31/2021","start_date":" 07/31/2021","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2021-05-28"}]